After listening to the shareholders meeting again, here are some of the key points I heard.
I recommend all shareholders take the time to listen. There is a lot more information than this.
- Milestones have not changed since September
- Collating data for IND response and for CTA filing
- CTA filing expected in Dec
- Quotient Clinical working on new drug formulations with focus on time release
- Several new drug formulations being developed for testing
- CTA dosing studies on new formulations starting 1Q15 (phase 1)
- Besides normal phase 1 safety data some PD (efficiacy) data will be taken
- Only about 3 months needed to complete the dosing studies
- On to Phase II studies, using appropriate drug formulations for specific selected targets
- During Q&A, Dr. Mullan said the board is focused on the financing issue but could not discuss yet.
I agree Dr Mullan seemed to be holding back some, especially in regards to the funding efforts, but my guess is when the CTA and IND trials get underway, we will hear a lot more, and shouldn't be very long from now.
When asked about the stock price and funding, Dr Mullan basically said (my words not his) he could not be specific (for obvious reasons) but be assured shareholders that the board was focused on addressing this issue.
I also got the impression several different drug formulations are in the works and when clinical trials start, feedback will be relatively rapid.
The press release says Mullan, MBBS, PhD, Chairman and CEO of Rock Creek Pharmaceuticals, will present preclinical and clinical data for anatabine citrate.
Hopefully this conference will be shortly after the CTA has been filed and the IND has been accepted by the FDA.
"So what do we need? First, we need to start the IND. That could happen very early next Q."
How about in December? Isn't that what the BioPharm presentation says?
Has that changed?
that JW is gonna buy it all back lock stock and barrel?
Have these clowns read the proxy statement?
JW is barely a 5% owner if you also want to include out of money warrant assumptions.
If you read the proxy statement, JW is a small shrimp in comparison to Tradewinds and McKeon.
But the shorts don't want to talk about that.
I wonder Why?
I would add that the most recent proxy says there are only 597 shareholders of record, but when you back out the large shareholders like Tradewinds, McKeon, JW, and the other close insiders, that does not leave many mom and pop shareholders.
This is why the shorts are so frustrated and are having a difficult time covering.
Got my proxy statement today in the mail. It shows 597 stockholders of record.
I checked last years proxy statement and it shows 606 stockholders of record.
Not much change, given the Jonnie circus.
Google – National Research Action Plan
“On August 31, 2012, President Obama issued an Executive Order (the Order) directing the Departments of Defense (DoD), Veterans Affairs (VA), Health and Human Services (HHS), and Education (henceforth referred to as “the agencies”), to develop a National Research Action Plan (NRAP) on posttraumatic stress disorder (PTSD), other mental health conditions, and Traumatic Brain Injury (TBI) “to improve the coordination of agency research into these conditions and reduce the number of affected men and women through better prevention, diagnosis, and treatment.”
If Roskamp has discovered Anatabine is a potential treatment for TBI what will the administration direct the FDA to do?
Any guess shorts?
Market was down on Friday but RCPI was up.
Then we hear about the TBI news this weekend.
Huge quantity on bid early Friday.